Compare CCSI & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CCSI | MNPR |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 683.1M | 587.4M |
| IPO Year | 2022 | 2019 |
| Metric | CCSI | MNPR |
|---|---|---|
| Price | $38.70 | $111.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | $37.50 | ★ $107.00 |
| AVG Volume (30 Days) | 142.8K | ★ 263.1K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.99 |
| EPS | ★ 2.72 | N/A |
| Revenue | ★ $349,696,000.00 | N/A |
| Revenue This Year | $3.33 | N/A |
| Revenue Next Year | $2.70 | N/A |
| P/E Ratio | $14.25 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $20.20 | $29.18 |
| 52 Week High | $41.40 | $124.82 |
| Indicator | CCSI | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 57.14 | 49.18 |
| Support Level | $32.75 | $102.88 |
| Resistance Level | $39.41 | $114.60 |
| Average True Range (ATR) | 1.87 | 6.56 |
| MACD | 0.08 | -1.78 |
| Stochastic Oscillator | 93.44 | 25.29 |
Consensus Cloud Solutions Inc is a provider of secure information delivery services with a scalable Software-as-a-Service SaaS platform. It is engaged in the fax cloud business. The company's offerings include communication, data extraction, and digital signature solutions that enable users to securely access, exchange, and manage information across organizational and geographic boundaries. It serves multiple industry verticals, including healthcare, government, financial services, legal, and education. Geographically, the company operates in the United States, Canada, Ireland, and other countries. It derives the maximum revenue from the United States.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.